Glenmark Pharma signed an Exclusive Licensing Agreement with Lotus International

Share Us

1452
Glenmark Pharma signed an Exclusive Licensing Agreement with Lotus International
20 Jan 2022
5 min read

News Synopsis

Glenmark Pharmaceuticals Ltd has announced that the Swiss arm of the company has signed an agreement with Lotus International Pte Ltd in order to commercialise its innovative nasal spray Ryaltris in Singapore, Hong Kong and Vietnam.

Under the agreement, Glenmark will be responsible for the manufacturing and supply of Ryaltris. Lotus, on the other hand, will be responsible for the commercialisation subject to receipt of regulatory approvals in these markets. Glenmark will receive the upfront payment along with the regulatory and sales-based milestone payments from Lotus.

The Chief Commercial Officer at Glenmark Pharmaceutical, Robert Crockart has said that this partnership will provide patients access to highly effective and proven treatment for allergic rhinitis in these key South-East Asian markets. He also said that this is the first brand product to get involved in Lotus respiratory portfolio with strong clinical data and IP protection.

Glenmark has also entered into commercial agreements with other partners around the world, including Menarini for the commercialisation of Ryaltris in selected EU markets.

TWN In-Focus